Purpose
The National Alliance Medical Director Advisory Council has been asked for guidance developing and piloting a sustainable process for the following:
- Review new drugs and therapies that are coming out in the marketplace and provide education to employers about their impact and how to best address the needs of their population.
- Review recent ICER report on comparative effectiveness research (CER) and help translate the relevant findings for employers and other purchasers, so they can best utilize these findings in their overall health care strategic planning. Explore considerations for inclusion of additional employer-relevant metrics in value analysis.
- Evaluate the potential development a value-based contract framework – that can inform and influence health plans/PBMs to more effectively align stakeholder interests.
- Suggest a recommended path forward and a dissemination approach for purchasers.